Methotrexate used as a steroid-sparing agent in non-renal chronic Henoch-Schönlein purpura.
Henoch-Schönlein purpura (HSP) is the most common form of systemic vasculitis in childhood and a small percentage of children develop a chronic form of the disease that often requires prolonged corticosteroid therapy. A detailed case description of a child with non-renal chronic HSP treated with methotrexate to allow for tapering of corticosteroids is presented. This represents the first report of methotrexate use in the treatment of chronic HSP.
Rettig
P
P
Children's Hospital of Philadelphia, Division of Rheumatology, Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
Cron
R Q
RQ
D000305:Adrenal Cortex Hormones / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D002908:Chronic Disease; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D006801:Humans; D011695:IgA Vasculitis / Q000175:diagnosis / Q000188:drug therapy*; D007279:Injections, Subcutaneous; D008134:Long-Term Care; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage*; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000305:Adrenal Cortex Hormones; D008727:Methotrexate